Biotechnology

New brain model enables testing of treatments for Parkinson’s

Scientists are inventing a small model that mimics the part of the brain that is affected by Parkinson’s disease. The model will improve our understanding of the disease and pave the way for testing new treatments. The technology could lead to the development of an implant.

Professor Jenny Emnéus from DTU Bioengineering leads the development of a brain model for Parkinson's. Photo: Thomas Steen Møller.

This solution opens up the possibility of developing technology for an implant that could be implanted in the brain of a patient with Parkinson’s disease. The researchers have now developed the first prototype, and it is ready for animal testing.

“The implant could potentially enable us to treat Parkinson’s in the exact part of the brain that’s affected. Today, patients are treated with oral medications. The medicine thus not only reaches the affected area but the entire brain, causing a number of unwanted side effects,” says Jenny Emnéus.

The DTU researchers are working together with researchers from Italy and Norway to develop a remote control that patients can use once they have had their implant inserted. The remote control needs to reach the implant and activate the light, thereby stimulating the release of dopamine while also measuring how much dopamine is released, when patients experience symptoms.

If the researchers are successful in developing the system, the questions still remains for how patients will manage their own doses.

“We imagine that the dopamine doses will be prescribed by a doctor, or that based on the patient’s symptoms, a doctor will prescribe the interval of the dopamine doses, so that patients do not end up putting a strain on their brain,” says Jenny Emnéus.

New treatment 10 years down the road

The OpenMIND research project has secured funding until 2025 and is expected to lead to the development of a test platform for other neurodegenerative diseases. Among other things, the test platform is to be made available to private companies for testing new medicines and treatments for diseases.

According to Jenny Emnéus, it will take at least ten years before the research will result in an actual treatment offer for patients.

Tema

Up to 12,000 people in Denmark have Parkinson’s disease, and according to Parkinsonforeningen (the Parkinson’s Association), 7-10 million people worldwide have the disease. Europe is facing a major challenge with an increasing number of elderly people in the population who will be affected by neurodegenerative diseases.

There is no cure for Parkinson’s disease, and existing treatments only relieve the symptoms. The underlying mechanisms of Parkinson’s disease still lack a thorough research-based description, partly because it is not possible to mimic human biology with the existing animal models.

Tema

DTU has a strong focus on the use of biotechnology within pharma and health, where biology and technology are utilized for early diagnosis of diseases as well as the development of new medicines and treatment methods.

Biotechnology is part of the life science area and research into this area is so extensive that it alone accounts for a third of the university's scientific publications. The latest national figures show that the biotech industry's total annual growth in this area is 6 %. This is three times higher than the average growth in the private business community.

Statistics Denmark's latest figures show a 30 % increase in the number of graduates with a long scientific education within technical sciences who are employed in the sector.

Read more in our special topic on biotechnology.

Contact

Jenny Emnéus Professor Department of Biotechnology and Biomedicine